Alector Inc Secures $133 mln in Series E Financing

South San Francisco-based Alector Inc, a biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, has raised $133 million in Series E financing. The investors included Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Polaris Partners, OrbiMed, MRL Ventures, GV and the Dementia Discovery Fund.

Leave a Reply